Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|October 25, 2022
Daily Dose: High-dose Flu Vaccine Consistently More Effective vs Standard-dose
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 24, 2022, we reviewed a study presented at IDWeek 2022, held from October 19 to 23, in Washington, DC.
The study
Researchers conducted a systematic review and meta-analysis, identifying 19 studies conducted over 11 consecutive influenza seasons from 2009 to 2020. The final pooled cohort numbered more than 45 million adults aged ≥65 years who had received either high- or standard-dose influenza vaccination.
The results
Receiving high-dose influenza vaccine was associated with greater relative efficacy and effecivenss vs receiving a standard-dose vaccine against probable or laboratory-confirmed influenza-like illnesses, hospital and ED visits, and influenza hospitalization.
High-dose influenza vaccines also conferred greater proection than standard-dose vaccines against hospitalizations for pneumonia, against influenza and pneumonia, and against respiratory, cardiovascular, cardiopulmonary, and all-cause events.
Results favored high-dose influenza vacccine in subanalyses stratified by dominant influenza strain, antigenic match, and study design and setting.
Clinical implications
“Evidence over 11 consecutive influenza seasons from both randomized and observational studies suggest HD-IIV [high-dose influenza vaccination] was consistently more effective than SD-IIV [standard-dose influenza vaccination] at reducing influenza and associated serious outcomes irrespective of recipient age and characteristics of the influenza season,” the researchers concluded.
Click here for the full study review.
Advertisement
Related to this article
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement